Dysphagia in Epilepsy Patients: The Silent Enemy
- PMID: 39399555
- PMCID: PMC11464231
- DOI: 10.1212/CPJ.0000000000200362
Dysphagia in Epilepsy Patients: The Silent Enemy
Erratum in
-
Erratum: Dysphagia in Epilepsy Patients: The Silent Enemy.Neurol Clin Pract. 2025 Feb;15(1):e200423. doi: 10.1212/CPJ.0000000000200423. Epub 2024 Nov 7. Neurol Clin Pract. 2025. PMID: 39524099 Free PMC article.
Abstract
Purpose of review: Dysphagia, or difficulty swallowing, affects several individuals globally and can contribute to a reduced quality of life and partial medication adherence, especially in patients with epilepsy. There is also a lack of awareness and understanding of dysphagia among both health care providers and patients. This review examines the interplay between dysphagia and epilepsy treatment and the potential for optimizing diagnosis and intervention.
Recent findings: Dysphagia, although a prevalent condition, is often underdiagnosed or misdiagnosed. Managing dysphagia involves patient and caregiver education on medication management techniques, lifestyle changes, and collaboration with a multidisciplinary health care team. There are also several modalities to screen and evaluate for dysphagia by using technology, using questionnaires, and asking probing questions. In patients with epilepsy, dysphagia can make swallowing certain formulations of antiseizure medications (ASMs) difficult or impossible-so, there is a need for tailored management strategies if discontinuing the medication is not feasible. Alternative formulations such as soluble, liquid, granular, or powder alternatives have been recognized as valuable options in addressing partial adherence due to dysphagia.
Summary: Patients with dysphagia may have varying symptoms, making it challenging for clinicians to accurately identify the condition. To address this issue, various questionnaires and assessments have been developed to uncover swallowing difficulties. Administration of alternate ASM formulations must consider options available for each individual.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Conflict of interest statement
J.W. Wheless - Speaker's Bureau: LivaNova, Eisai, Supernus, Jazz, UCB, Neurelis, Biomarin, SKLSI, Azurity. Consulting: Jazz, Neurelis, Marinus, Biomarin, Azurity. Grants: Shainberg Foundation, TSC Alliance, NIH, Neuro Event Labs, Envision, Stoke, Xenon, Neurelis, Marinus, Epiwatch, SKLSI, Longboard, Biohaven; B. Richardson reports no disclosures; C. Rubinos - Speaker's Bureau: Marinus; E. Faught - Grant: UCB. Consultant: Azurity, Biogen, LivaNova, Neurelis, SK Life Science; M. Vuong reports no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
References
-
- Wolf DC. Dysphagia. In: Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Butterworths; 1990. Accessed October 24, 2023. ncbi.nlm.nih.gov/books/NBK408/ - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials